The IRP model helps companies understand how reference pricing and parallel trade can impact product revenues and allows them to determine the optimal launch sequence for new medicines.
Our easy to use and dynamic model helps companies through this important decision-making process. All of the model inputs can be varied to enable companies to quickly run multiple scenarios in order to determine their optimal commercial strategy. The model provides quarterly revenue forecasts up to 10 years into the future.
Cost for MAP Members: 12,000
Cost for Non-Members: 25,000
Kyowa Kirin, VP Rare Diseases, International Franchise Head